Pathways to market for new drugs and medical devices
There have been many recent developments in the way drugs and medicines are produced and delivered, accompanied by a greater focus on drugs that are tailored to an individual’s own disease and biology. Two different responses from the Australian Government are investigating whether changes need to be made to our systems for evaluating and approving drugs, technologies and health services.
Health Minister Greg Hunt has tasked the House of Representatives Standing Committee on Health, Aged Care and Sport with an Inquiry into approval processes for new drugs and novel medical technologies in Australia. The inquiry will consider the following topics:
- The range of new drugs and emerging novel medical technologies in development;
- Incentives to research, develop and commercialise new drugs and novel medical technologies for conditions where there is an unmet need;
- How to make Australia a more attractive location for clinical trials for new drugs and novel medical technologies; and
- whether the approval process for new drugs and novel medical technologies could be made more efficient.
Submissions to the Inquiry are due on 13 October. More information, including the full Terms of Reference, is available here.
The HSRAANZ would be interested to receive members' views on this issue and they can be submitted to email@example.com.